# Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions

> **NCT04848714** · PHASE1 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 16 (actual)

## Conditions studied

- Latrodectism

## Interventions

- **DRUG:** ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL

## Key facts

- **NCT ID:** NCT04848714
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2021-08-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04848714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04848714, "Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04848714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*